ArticlePharmacoEconomics - open2025

Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England.

Vasileios Kontogiannis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.